Cargando…
A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer
Lewis Y antigen, a glycan highly expressed on most epithelial cancers, was targeted for cancer treatment but lacked satisfactory results in some intractable and refractory cancers. Thus, it is highly desirable to develop an effective therapy against these cancers, hopefully based on this target. In...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393954/ https://www.ncbi.nlm.nih.gov/pubmed/34440263 http://dx.doi.org/10.3390/biomedicines9081059 |
_version_ | 1783743841487028224 |
---|---|
author | Chen, Jie Pan, Zhidi Han, Lei Zhou, Yuexian Zong, Huifang Wang, Lei Sun, Rui Jiang, Hua Xie, Yueqing Yuan, Yunsheng Wu, Mingyuan Bian, Yanling Zhang, Baohong Zhu, Jianwei |
author_facet | Chen, Jie Pan, Zhidi Han, Lei Zhou, Yuexian Zong, Huifang Wang, Lei Sun, Rui Jiang, Hua Xie, Yueqing Yuan, Yunsheng Wu, Mingyuan Bian, Yanling Zhang, Baohong Zhu, Jianwei |
author_sort | Chen, Jie |
collection | PubMed |
description | Lewis Y antigen, a glycan highly expressed on most epithelial cancers, was targeted for cancer treatment but lacked satisfactory results in some intractable and refractory cancers. Thus, it is highly desirable to develop an effective therapy against these cancers, hopefully based on this target. In this work, we constructed a novel T cell-engaging bispecific antibody targeting Lewis Y and CD3 (m3s193 BsAb) with the IgG-[L]-scfv format. In vitro activity of m3s193 BsAb was evaluated by affinity assay to target cells, cytotoxicity assay, cytokines releasing assay, and T cells proliferation and recruiting assays. Anti-tumor activity against gastric cancer was evaluated in vivo by subcutaneous huPBMCs/tumor cells co-grafting model and huPBMCs intravenous injecting model. In vitro, m3s193 BsAb appeared to have a high binding affinity to Lewis Y positive cells and Jurkat cells. The BsAb showed stronger activity than its parent mAb in T cell recruiting, activation, proliferation, cytokine release, and cytotoxicity. In vivo, m3s193 BsAb not only demonstrated higher therapeutic efficacy in the huPBMCs/tumor co-grafting gastric carcinoma model than the parent mAb but also eliminated tumors in the model of intravenous injection with huPBMCs. Strong anti-tumor activity of m3s193 BsAb revealed that Lewis Y could be targeted in T cell-engaging BsAb for gastric cancer therapy. |
format | Online Article Text |
id | pubmed-8393954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83939542021-08-28 A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer Chen, Jie Pan, Zhidi Han, Lei Zhou, Yuexian Zong, Huifang Wang, Lei Sun, Rui Jiang, Hua Xie, Yueqing Yuan, Yunsheng Wu, Mingyuan Bian, Yanling Zhang, Baohong Zhu, Jianwei Biomedicines Article Lewis Y antigen, a glycan highly expressed on most epithelial cancers, was targeted for cancer treatment but lacked satisfactory results in some intractable and refractory cancers. Thus, it is highly desirable to develop an effective therapy against these cancers, hopefully based on this target. In this work, we constructed a novel T cell-engaging bispecific antibody targeting Lewis Y and CD3 (m3s193 BsAb) with the IgG-[L]-scfv format. In vitro activity of m3s193 BsAb was evaluated by affinity assay to target cells, cytotoxicity assay, cytokines releasing assay, and T cells proliferation and recruiting assays. Anti-tumor activity against gastric cancer was evaluated in vivo by subcutaneous huPBMCs/tumor cells co-grafting model and huPBMCs intravenous injecting model. In vitro, m3s193 BsAb appeared to have a high binding affinity to Lewis Y positive cells and Jurkat cells. The BsAb showed stronger activity than its parent mAb in T cell recruiting, activation, proliferation, cytokine release, and cytotoxicity. In vivo, m3s193 BsAb not only demonstrated higher therapeutic efficacy in the huPBMCs/tumor co-grafting gastric carcinoma model than the parent mAb but also eliminated tumors in the model of intravenous injection with huPBMCs. Strong anti-tumor activity of m3s193 BsAb revealed that Lewis Y could be targeted in T cell-engaging BsAb for gastric cancer therapy. MDPI 2021-08-20 /pmc/articles/PMC8393954/ /pubmed/34440263 http://dx.doi.org/10.3390/biomedicines9081059 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Jie Pan, Zhidi Han, Lei Zhou, Yuexian Zong, Huifang Wang, Lei Sun, Rui Jiang, Hua Xie, Yueqing Yuan, Yunsheng Wu, Mingyuan Bian, Yanling Zhang, Baohong Zhu, Jianwei A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer |
title | A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer |
title_full | A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer |
title_fullStr | A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer |
title_full_unstemmed | A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer |
title_short | A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer |
title_sort | novel bispecific antibody targeting cd3 and lewis y with potent therapeutic efficacy against gastric cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393954/ https://www.ncbi.nlm.nih.gov/pubmed/34440263 http://dx.doi.org/10.3390/biomedicines9081059 |
work_keys_str_mv | AT chenjie anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT panzhidi anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT hanlei anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT zhouyuexian anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT zonghuifang anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT wanglei anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT sunrui anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT jianghua anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT xieyueqing anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT yuanyunsheng anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT wumingyuan anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT bianyanling anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT zhangbaohong anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT zhujianwei anovelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT chenjie novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT panzhidi novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT hanlei novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT zhouyuexian novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT zonghuifang novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT wanglei novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT sunrui novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT jianghua novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT xieyueqing novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT yuanyunsheng novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT wumingyuan novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT bianyanling novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT zhangbaohong novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer AT zhujianwei novelbispecificantibodytargetingcd3andlewisywithpotenttherapeuticefficacyagainstgastriccancer |